Key result
This article reviews trials comparing the antiproteinuric and antihypertensive effects of combination therapy with ACE inhibitors and ARBs versus either drug class alone in kidney disease.
Why the study?
Does combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce blood pressure and proteinuria compared to monotherapy in patients with kidney disease?
Does combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce blood pressure and proteinuria compared to monotherapy in patients with kidney disease?
This review discusses the evidence and mechanisms for using combination ACEi and ARB therapy to reduce blood pressure and proteinuria in kidney disease.
Combination therapy may enhance proteinuria reduction in kidney disease; leaves open long-term safety and outcome benefits.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers each reduce proteinuria and blood pressure. Several studies have compared the antiproteinuric and antihypertensive effects of combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with those of therapy with either drug class alone. This article reviews those trials as well as evidence suggesting a mechanism for the benefits observed with combination therapy.
No takes yet. Share an insight, caveat, or question.
Stuart L. Linas (2008) conducted a review in Kidney Disease. Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers vs. Either drug class alone was evaluated on Proteinuria and blood pressure. This article reviews trials comparing the antiproteinuric and antihypertensive effects of combination therapy with ACE inhibitors and ARBs versus either drug class alone in kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: